

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/561,009		ATTY. DOCKET NO.: V0005.70102US00	
				FILING DATE: June 21, 2007		CONFIRMATION NO.: 6040	
				APPLICANT: Jason Gray			
				GROUP ART UNIT: 1624		EXAMINER: Brenda Libby Coleman	
Sheet	1	of	1				

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
/B.C./		5,229,382		Chakrabarti <i>et al.</i>	07-20-1993

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
/B.C./		[No Author Listed] Definition of "Typically". Encarta Dictionary. Microsoft. 2009: 1 page. Last accessed 7/11/2009.	
/B.C./		[No Author Listed] ICH harmonized tripartite guideline. Specifications: Test procedures and acceptance criteria for new drug substance and new drug products: Chemical substances Q6A. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Oct 1999: 26 pages.	
/B.C./		[No Author Listed] Olanzapine. The Merck Index. Entry for Olanzapine. 2006, 14 th Edition: 1 page.	
/B.C./		[No Author Listed] Remington: The science and practice of pharmacy. 2006, 21st Edition: 892.	duplicate
/B.C./		[No Author Listed] "Freeze Drying". Available at http://en.wikipedia.org/wiki/Freeze_drying . Last accessed 05/19/2008.	
/B.C./		BYRN <i>et al.</i> , Pharmaceutical solids: a strategic approach to regulatory considerations. Pharmaceutical Research.1995;12(7):945-954.	
/B.C./		YU, Amorphous pharmaceutical solids: preparation, characterization and stabilization. Advanced Drug Delivery Reviews. 2001;48:27-42.	

EXAMINER: /Brenda Coleman/	DATE CONSIDERED: 11/23/2010
-----------------------------------	------------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR § 1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR § 1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR § 1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. § 120.]